Bent on Biologics: Attacking the Pathogenesis

Fledgling drugs like infliximab offer more hope than traditional methods

Related Videos
Related Content

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

POLL: What Topics Did You Most Enjoy at AAD 2023?

March 27th 2023

Lanolin Named Allergen of the Year

March 27th 2023

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

POLL: What Topics Did You Most Enjoy at AAD 2023?

March 27th 2023

Lanolin Named Allergen of the Year

March 27th 2023

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

POLL: What Topics Did You Most Enjoy at AAD 2023?

March 27th 2023

Lanolin Named Allergen of the Year

March 27th 2023
© 2023 MJH Life Sciences

All rights reserved.